GSK is the fifth company to leave BIO in roughly a year, a group that includes Pfizer (PFE). The departures coincided with a drop in lobbying spending from the group and other challenges, STAT says.

GSK is the fifth company to leave BIO in roughly a year, a group that includes Pfizer and UCB. The departures coincided with ...

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced 48-week findings from the DOLCE study, sponsored by Fundación ...

This story first appeared in The Readout newsletter. Sign up for The Readout and receive STAT’s award-winning biotech news ...

Pacific Trade Invest NZ invites you to an important webinar on the FMCG industry in New Zealand. This will be of great ...

GSK’s departure comes as the industry anticipates the incoming Trump administration and as it continues to grapple with the threat of the BIOSECURE Act and losses of legal challenges to the IRA’s drug ...

A family-friendly concept is highlighted at the China International Import Expo, ranging from disease care, driving safety and baby's products.Medical professionals, sociologists, health officials, en ...

GSK confirmed this morning that the disappointing readout from the DREAMM-3 trial of multiple myeloma therapy Blenrep reported earlier this month means that it will take the drug off the US market.

The global auto-injectors market is set to reach a significant valuation of US$ 30,578.2 million in 2023, marking a strong ...

The global cold, cough, and sore throat remedy market is poised for steady growth, with a projected CAGR of 3.40% from 2024 to 2034. The market is estimated to be valued at US$ 42,618.7 million in ...